Colgate Palmolive Co.
- CL · NYSE
- Perfumes, Cosmetics & Other Toilet Preparations
- New York, NY
- 33,600 employees
- CIK 0000021665
Updated from SEC filings through
Top things to know
Executives
-
Noel R. Wallace Chairman, President & CEO 4, 2026-09-18 -
Stanley J. Sutula Iii Chief Financial Officer 4, 2026-09-18 - Jennifer M. Daniels Chief Financial Officer As Attorney-in-Fact (c) Principal Accounting Officer 10-K, 2026-02-23
-
John Hazlin Chief Growth Officer 4, 2026-09-18 -
Sally Massey Chief People Officer 4, 2026-09-18 -
Gregory O. Malcolm Executive Vice President, Controller 10-K, 2026-02-23
Colgate Palmolive Co is a U.S. public company in perfumes, cosmetics & other toilet preparations (SIC 2844), headquartered in New York, NY. It trades as CL on NYSE. Revenue was $20.4B in the fiscal year ending December 31, 2025, +1.4% from the year before. It reported about 33,600 employees. Noel R. Wallace is Chairman, President & CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $20.4B 10-K, 2026-02-23 | $20.1B 10-K, 2026-02-23 | $19.5B 10-K, 2026-02-23 | $18.0B 10-K, 2025-02-13 | $17.4B 10-K, 2024-02-15 |
| Operating income | $3.3B 10-K, 2026-02-23 | $4.3B 10-K, 2026-02-23 | $4.0B 10-K, 2026-02-23 | $2.9B 10-K, 2025-02-13 | $3.3B 10-K, 2024-02-15 |
| SG&A | $7.9B 10-K, 2026-02-23 | $7.7B 10-K, 2026-02-23 | $7.2B 10-K, 2026-02-23 | $6.6B 10-K, 2025-02-13 | $6.4B 10-K, 2024-02-15 |
| Net income | $2.1B 10-K, 2026-02-23 | $2.9B 10-K, 2026-02-23 | $2.3B 10-K, 2026-02-23 | $1.8B 10-K, 2025-02-13 | $2.2B 10-K, 2024-02-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Noel R. Wallace | Chairman, President & CEO | 4, 2026-09-18 |
 Christopher S. Boerner | Board member (per proxy) bio: Independent Board Chair and Chief Executive Officer, | DEF 14A, 2026-03-25 |
| Stanley J. Sutula Iii | Chief Financial Officer | 4, 2026-09-18 |
| Brian O. Newman | Board member (per proxy) bio: Independent Executive Vice President and Chief Financial Officer, | DEF 14A, 2026-03-25 |
| Martina Hund-Mejean | Board member (per proxy) bio: Independent Former Chief Financial | DEF 14A, 2026-03-25 |
| Jennifer M. Daniels | Chief Financial Officer As Attorney-in-Fact (c) Principal Accounting Officer | 10-K, 2026-02-23 |
| John Hazlin Chief Growth Officer | Chief Growth Officer | 4, 2026-09-18 |
| Sally Massey Chief People Officer at Colgate-Palmolive | Chief People Officer | 4, 2026-09-18 |
| Gregory O. Malcolm | Executive Vice President, Controller | 10-K, 2026-02-23 |
| Panagiotis Tsourapas Chief Operating Officer at Colgate Palmolive | COO, CD, EMEA, APac, Skin | 4, 2026-09-18 |
 Shane Grant Chief Operating Officer, Americas, Colgate-Palmolive | COO, Americas | 4, 2026-09-18 |
| Gregory Malcolm | EVP and Controller | 4, 2026-09-18 |
| Betsy Fishbone Chief Legal Officer and Secretary at Colgate-Palmolive Company | CLO and Secretary | 4, 2026-09-18 |
| C. Martin Harris | Board member (per proxy) bio: Independent Special Counsel to | DEF 14A, 2026-03-25 |
| John P. Bilbrey | Board member (per proxy) bio: Independent Executive Chair of | DEF 14A, 2026-03-25 |
| John T. Cahill | Board member (per proxy) bio: Independent Chair, The Kraft Heinz | DEF 14A, 2026-03-25 |
What Colgate Palmolive Co does
Colgate-Palmolive Company (together with its subsidiaries, “we,” “us,” “our,” the “Company” or “Colgate-Palmolive”) is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 794.9 million (as of September 30, 2026) | 10-Q, October 30, 2026 |
|---|---|---|
| Public float | $73.4B (as of June 30, 2025) | 10-K, February 23, 2026 |
| Reportable segments | 2 (period ending September 30, 2026) | 10-Q, October 30, 2026 |
| Latest proxy statement | Meeting May 8, 2026 (filed March 25, 2026) | DEF 14A, March 25, 2026 |
| Auditor | PricewaterhouseCoopers LLP (New York, New York) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 5, 2026 | Lorrie M. Norrington Director | Sale | 4,170 | $414K | Form 4, November 9, 2026 |
| November 5, 2026 | Noel R. Wallace Chairman, President & CEO | Sale | 20,000 | $2.0M | Form 4, November 6, 2026 |
| November 4, 2026 | Panagiotis Tsourapas COO, CD, EMEA, APac, Skin | Sale | 19,938 | $2.0M | Form 4, November 6, 2026 |
| November 4, 2026 | John Hazlin Chief Growth Officer | Sale | 23,376 | $2.3M | Form 4, November 6, 2026 |
| August 24, 2026 | Panagiotis Tsourapas COO, CD, EMEA, APac, Skin | Sale | 10,000 | $921K | Form 4, August 26, 2026 |
| August 6, 2026 | John T. Cahill Director | Sale | 4,170 | $389K | Form 4, August 7, 2026 |
| August 5, 2026 | Noel R. Wallace Chairman, President & CEO | Sale | 322,042 | $29.7M | Form 4, August 6, 2026 |
| May 15, 2026 | Gregory Malcolm EVP and Controller | Sale | 2,300 | $203K | Form 4, May 18, 2026 |
Recent 8-K events
- 8-K filed 2026-10-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-31
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-13
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-01
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 2.05 Costs associated with exit or disposal activities (restructuring)
- 8-K filed 2026-04-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-17
- Item 8.01 Other events
- 8-K filed 2026-03-12
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-01-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-10
- Item 8.01 Other events
- 8-K filed 2025-10-31
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 2.05 Costs associated with exit or disposal activities (restructuring)
Frequently asked questions about Colgate Palmolive Co
- What does Colgate Palmolive Co do?
- In its own words, from Item 1 of its 10-K: "Colgate-Palmolive Company (together with its subsidiaries, “we,” “us,” “our,” the “Company” or “Colgate-Palmolive”) is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet."
- What is Colgate Palmolive Co's revenue?
- $20.4B for the fiscal year ending December 31, 2025, from its 10-K filed February 23, 2026.
- Is Colgate Palmolive Co profitable?
- Colgate Palmolive Co reported net income of $2.1B for the fiscal year ending December 31, 2025.
- How many employees does Colgate Palmolive Co have?
- About 33,600 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Colgate Palmolive Co?
- Noel R. Wallace, Chairman, President & CEO, as named in a 4 filed September 18, 2026.
- Who is the CFO of Colgate Palmolive Co?
- Stanley J. Sutula Iii, Chief Financial Officer, as named in a 4 filed September 18, 2026.
- Where is Colgate Palmolive Co headquartered?
- New York, NY.
- What is Colgate Palmolive Co's stock ticker?
- CL on NYSE.
- What industry is Colgate Palmolive Co in?
- Perfumes, Cosmetics & Other Toilet Preparations, SIC code 2844.
- What is Colgate Palmolive Co's website?
- colgatepalmolive.com. Investor relations: https://investor.colgatepalmolive.com/.
- When does Colgate Palmolive Co report earnings next?
- January 29, 2027. Source: estimate_8k_pattern.
- Is Colgate Palmolive Co a public company?
- Yes. Colgate Palmolive Co files with the SEC under CIK 0000021665 and trades as CL.
- Who audits Colgate Palmolive Co?
- PricewaterhouseCoopers LLP, New York, New York, as named in its latest annual report (10-K).
- How many shares of Colgate Palmolive Co are outstanding?
- 794.9 million shares as of September 30, 2026, from its 10-Q filed October 30, 2026.
- What is Colgate Palmolive Co's public float?
- $73.4B as of June 30, 2025, as reported on the cover of its 10-K filed February 23, 2026.
- How many business segments does Colgate Palmolive Co report?
- 2 reportable segments for the period ending September 30, 2026, from its 10-Q filed October 30, 2026.
- When is Colgate Palmolive Co's annual shareholder meeting?
- May 8, 2026, per its proxy statement (DEF 14A) filed March 25, 2026.
- Have Colgate Palmolive Co insiders traded stock recently?
- Since November 21, 2025, officers and directors reported 17 open-market sales worth about $63.8M and 0 purchases on Forms 4 and 5. The most recent: Lorrie M. Norrington (Director) sold 4,170 shares on November 5, 2026.